Fatal toxic epidermal necrolysis and severe granulocytopenia following therapy with cefuroxime

Acta Dermatovenerologica Croatica

Volumn 16, Issue 3, 2008, Pages 133-137

  Grgurević, Ivica ^a   Pejša, Vlatko ^a   Morović Vergles, Jadranka ^a   Dobrić, Ivan ^b   Gašparović, Vladimir ^b   Tudorić, Neven ^a  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Cefuroxime; Chronic; Epidermal necrolysis; Furosemide; Kidney failure; Neutropenia; Stevens Johnson syndrome; Toxic

Indexed keywords

CEFUROXIME AXETIL; CIPROFLOXACIN; FISH OIL; FUROSEMIDE; GENTAMICIN; LORATADINE; METHYLPREDNISOLONE;

AGED; ARTHRALGIA; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG FATALITY; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GRANULOCYTOPENIA; HUMAN; INTENSIVE CARE; MALAISE; MULTIPLE ORGAN FAILURE; PLASMAPHERESIS; PRURITUS; RASH; SEPSIS; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URINARY TRACT INFECTION;

AGED; AGRANULOCYTOSIS; ANTI-BACTERIAL AGENTS; CEFUROXIME; EPIDERMAL NECROLYSIS, TOXIC; FATAL OUTCOME; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; URINARY TRACT INFECTIONS;

EID: 51949099334     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. nd edition. Berlin: Springer; 2000. pp. 414-6.
2. Becker DS. Toxic epidermal necrolysis. Lancet 1998;351:1417-22.
3. Rzany B, Mockenhaupt M, Baur S, Schroder W, Stacker U, Mueller J, et al. Epidemiology of erythema exudativum multiforme majus, Stevens Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population based registry. J Clin Epidemiol 1996;49:769-73.
4. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000;1:349-60.
5. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42.
6. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991;127:839-42.
7. Chan HL, Stern RS, Arndt KA, Langloid J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43-7.
8. Naldi L, Locati F, Marchesi L, Cainelli T Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990;126:1103-4.
9. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
10. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR Study. J Invest Dermatol 2008;128:35-44.
11. Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993;129:466-8.
12. Guillaume J, Roujeau J, Revuz J, Penso D, Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell syndrome). Arch Dermatol 1987;123:1166-70.
13. Roujeau JC, Albengres E, Moritz S, Piacentino A, Cuny M, Revuz J, et al. Lymphocyte transformation test in drug-induced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol 1985;78:22-4.
14. Tegelberg-Stassen MJ, van Vloten WA, Baart de la Faille H. Management of nonstaphylococcal toxic epidermal necrolysis: follow-up study of 16 case histories. Dermatologica 1990;180:124-9.
15. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiological aspects. J Am Acad Dermatol 1991;25:778-86.
16. Arevalo JM, Lorente JA, Gonzales-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000;48:473-8.
17. Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458-61.
18. Prins C, Kerdel FA, Padilla RS, Huntiker T, Chimenti S, Viard I, et al.; TEN-IVIG Study Group. Toxic epidermal necrolysis - intravenous immunoglobulin. Arch Dermatol 2003;139:26-32.
19. Revuz J, Penso D, Roujeau J, Guillaume JC, Payne CK, Wechsler J, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-5.
20. Westly ED, Wechsler HL. Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator. Arch Dermatol 1984;120:721-6.
21. Yossepowitch O, Amir G, Safadi R, Lossos I. Ischemic hepatitis associated with toxic epidermal necrolysis in a cirrhotic patient treated with cefuroxime. Eur J Med Res 1997;2:182-4.
22. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.
23. GlaxoSmithKline. Ceftin (cefuroxime axetil tablets). Prescribing information, www.gsk.com
24. Perry CM, Brogden RN. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1996;52:125-58.
25. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6.
26. Kelemen JJ, Cioffii WG, McManus WF, Mason ADJ, Pruitt BAJ. Bum center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:273-8.
27. Helebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-12.
28. Rzany B, Schmitt H, Schopf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol (Stockh) 1991;71:171-2.
29. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008;58:33-40.